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Abstract 
Background: Neonatal sepsis caused by multidrug‑resistant gram‑negative bacteria has been reported in different 
parts of the world. It is a major threat to neonatal care, carrying a high rate of morbidity and mortality. While Colistin is 
the treatment of choice, few studies have reported its use in neonatal patients.
Methods: A retrospective descriptive study of all neonatal patients who had multidrug‑resistant Acinetobacter sepsis 
and were treated with Colistin over a 2‑year period. Patients’ charts and hospital laboratory data were reviewed.
Results: During the study period, 21 newborns were treated with Colistin. All had sepsis evident by positive blood 
culture and clinical signs of sepsis. The median gestational age and birth weight were 33 weeks (26–39) and 1700 g 
(700–3600), respectively. Nine (43 %) were very low birth weight infants. Eighteen (86 %) were preterm infants. 
Nineteen (91 %) newborns survived. No renal impairment is documented in any of our patients. Fourteen (67 %) of 
our patients had elevated eosinophil counts following Colistin treatment, for those patients, the average eosinophilic 
counts ± standard deviation before and after Colistin therapy were 149.08 ± 190.38 to 1193 ± 523.29, respectively, 
with a p value of less than 0.0001.
Conclusion: Our study showed that Colistin was both effective and safe for treating multidrug‑resistant Acineto‑
bacter neonatal sepsis. This is a retrospective study. No universal protocol was used for the patients. The factors that 
might affect the response or cause side effects are difficult to evaluate.
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Background
Neonatal sepsis caused by multidrug-resistant gram-neg-
ative bacteria has been reported in different parts of the 
world [1–5]. It is a major threat to neonatal care, carry-
ing a high rate of morbidity and mortality [6–9]. While 
Colistin is the treatment of choice, [10, 11] few studies 
have reported its use in neonatal patients [12–14]. The 
treatment protocol, safety and efficacy have not yet been 
established.
In this study, we will report our unit’s experience on 
the use of Colistin to treat neonatal gram-negative sep-
sis caused by multidrug-resistant Acinetobacter. We 
describe the treatment protocol and report the side 
effects and response to therapy.
Methods
The design was a retrospective descriptive study of all 
neonatal patients who had multidrug-resistant Acineto-
bacter sepsis and were treated with Colistin over a 2-year 
period. It was conducted at a level 3 neonatal unit in 
Amman - Jordan that had a capacity of 30 beds.
This paper is part of the neonatal sepsis study and was 
approved by the deanship of scientific research.
All neonates with blood culture-proven sepsis from 
multidrug-resistant Acinetobacter were identified. Those 
treated with Colistin were included.
Patients’ charts and hospital laboratory data were 
reviewed. Patients’ demographics, culture results, 
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antimicrobial sensitivity patterns, laboratory investiga-
tion results, Colistin dose, frequency, duration of treat-
ment, co-administered antibiotics, follow-up blood 
culture results and mortality were recorded.
Sepsis is defined as a positive blood culture with the 
presence of clinical signs of sepsis. Late-onset sepsis is 
defined as sepsis occurring after 72 h of life.
The indications for Colistin were the following: docu-
mentation of Carbapenems-resistant gram-negative bac-
teria in the blood culture or empirically when newborns 
present with septic shock during an outbreak of multid-
rug-resistant gram-negative sepsis.
Response to treatment was divided into clinical and 
microbiological response. The clinical response was 
defined as resolution of symptoms and survival. The 
microbiological response was defined as a negative blood 
culture post-Colistin therapy.
Central line-associated bloodstream infection 
(CLABSI) is defined as sepsis with a central line in situ or 
if the central line was present up to 48 h before the date 
of a positive blood culture.
SPSS® version 21 (SPSS Inc., Chicago, IL, USA) was 
used to conduct statistical analyses. p values <0.05 were 
considered statistically significant.
Results
During the study period, 21 newborns were treated with 
Colistin. All had sepsis evident by positive blood culture 
and clinical signs of sepsis.
All septic episodes were caused by Acinetobacter spe-
cies. Nineteen (90  %) were Carbapenems resistant. All 
were sensitive to Colistin.
The median gestational age and birth weight were 
33  weeks (26–39) and 1700  g (700–3600), respectively. 
Nine (43 %) were very low birth weight infants. Eighteen 
(86  %) were preterm infants. The characteristics of the 
newborn patients who received intravenous Colistin are 
presented in Table 1.
Intravenous Colistin was started for late-onset sepsis in 
all patients, with median post-natal age of 10 days (4–30). 
The average duration from presentation to the start of 
Colistin therapy was 2.5 (1–6) days. The average daily 
dose was 70,000  IU/kg/D (30,000–75,000). The average 
duration of treatment was 17 days (10–21).
Nineteen (91 %) newborns survived. Nineteen patients 
had follow-up blood culture to document clearance. All 
had negative cultures with an average duration for clear-
ance of 3 days (range 1–8). One patient continued to have 
positive culture until day 8 of treatment.
Colistin was administered, with other medications at 
some time during the treatment for all patients (Table 2). 
With respect to coverage for gram-negative bacte-
ria, none of our patients had Colistin as monotherapy. 
Eighteen (86  %) received Colistin with Imipenem and 
Amikacin/Gentamicin for the entire duration of treat-
ment. One patient received Colistin with Amikacin for 
the entire duration of treatment. One patient received 
Colistin with Imipenem for the entire treatment dura-
tion, and one patient was treated with Imipenem and 
Amikacin for the first week of treatment; then, the 
patient received Colistin alone for the second week.
No renal impairment is documented in any of our 
patients. The mean creatinine and standard deviation for 
our patients during pre- and post-Colistin administra-
tion were 0.47 (0.7) and 0.27 (0.35) mg/dL, respectively 
Table 1 Clinical characteristics of  neonates with  multi-
drug-resistant Acinetobacter sepsis who were treated 
with Colistin
VLBW very low birth weight, PROM prolonged rupture of membranes, CLABSI 
central line associated blood stream infection
Preterm <37 weeks 18 (86 %)
Gestational age—median (range) 33 (26–40)
Birth weight—mean (range) 1700 (800–3600)
VLBW 9 (43 %)
Male gender 13 (62 %)
Pre‑eclampsia 3 (14 %)
PROM 3 (14 %)
Cesarean section 16 (76 %)
Apgar scores‑ mean (range) (min)
 1 7 (3–8)
 5 9 (7–9)
CLABSI number (%) 14 (67 %)
Late sepsis number (%) 21 (100 %)
Mean age at sepsis (days) 10 (4–30)
Carpapenems resistance (%) 19 (90 %)
Day of sepsis Colistin started 2.5 (1–6)
Treatment duration (days) 17(10–21)
Dose U/kg/day 70,000 (30,000–75,000)
Day of microbiological clearance—mean (range) 3 (1–8)
Mortality (%) 2 (9.5 %)
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(p value 0.249). None of the patients had a post-Colistin 
creatinine elevation of more than 0.5 mg/dL.
Three patients developed one episode of hypoka-
lemia, two had one episode of hypocalcaemia, and two 
had hyponatremia; only nine patients had their mag-
nesium levels measured during treatment, and two of 
them had hypomagnesaemia. Fourteen (67  %) of our 
patients had elevated eosinophil counts following Colis-
tin treatment, for those patients, the average eosinophilic 
counts  ±  standard deviation before and after Colistin 
therapy were 149.08 ± 190.38 to 1193 ± 523.29, respec-
tively, with a p value of less than 0.0001 (Fig. 1).
Discussion
Our study showed that Colistin was both effective and 
safe for treating multidrug-resistant Acinetobacter neo-
natal sepsis.
Twenty-one newborn infants received Colistin and had 
sepsis demonstrated by blood culture. All cases had Aci-
netobacter species, and 19 were Carbapenems-resistant 
Acinetobacter species.
Thus far, this is the only study in which all newborns 
had Acinetobacter-proven sepsis by blood culture. 
Twenty-one preterm infants treated with Colistin were 
reported by Alan et  al., and only nine of those had a 
positive blood culture [12]. In a report by Jajoo et  al., 
only 13 newborns had Acinetobacter isolated from 
blood samples [13]. Isolation of certain pathogens from 
places other than the blood might reflect colonization. 
In addition, newborns who were treated empirically 
might have causes for their sepsis beyond multidrug-
resistant gram-negative bacteria, and they might not 
have bacterial sepsis. Our study reports the largest 
series of newborns with sepsis from multidrug-resist-
ant Acinetobacter according to blood culture who were 
treated with Colistin.
We did not use a loading dose in our protocol, which 
is similar to previous reports [12–14]. The average dose 
was 70,000 IU/kg/day, and most of our patients received 
75,000  IU/kg/day. This dose is higher than previously 
reported doses [12–14]. The lowest dose was 30,000  IU/
kg/D, and the baby who received this dose survived with 
microbiological clearance after 2 days of treatment.
In our population, the clinical efficacy was 91 %. Nine-
teen newborns had follow-up blood cultures. Micro-
biological clearance was documented in all of them. The 
average time for negative culture was 3 days. Two new-
born infants had clearance documented after 8  days of 
treatment; one of them did not have follow-up cultures 
until day 8 and had a stable course, while the other had 
cultures drawn every 2 days, all of which grew Acineto-
bacter until day 8. Unfortunately, this baby died. During 
the study period, there was no protocol for repeating 
blood cultures, which might contribute to the variable 
time to clearance.
The survival rate reported in our study is higher than 
previous reports [12, 13]. This might be from the higher 
Colistin dose than previous reports [12, 13]. Additionally, 
the day for when Colistin treatment was initiated for sep-
sis was not reported in other studies. Our babies might 
have been started on treatment earlier.
Nephrotoxicity is the most commonly reported adverse 
effect of Colistin therapy [15, 16]. Previous studies on the 
neonatal population have reported acute kidney injury 
and electrolyte disturbances [12, 13]. In our series of 
patients, there was no evidence of acute kidney injury 
and the electrolyte imbalances were insignificant.
Fourteen (67  %) patients in our study had an elevated 
eosinophilic count following Colistin treatment. Because 
the treatment team did not note this during treatment, 
no clinical correlation was made between the increase in 
eosinophil count and symptoms. Additionally, few patients 
had a follow-up CBC after the end of treatment. As a 
result, recovery to normal count could not be documented. 
An allergic reaction to Colistin was previously reported, 
which varies between mild itching and episodes of rash to 
cough, sore throat and bronchoconstriction [17–19]. Only 
two reports of eosinophilia were found. In an old study, 
two adult patients developed eosinophilia [20]. Recently 
there was another report of an elderly lady who developed 
hypersensitivity pneumonitis [21]. This is the first report 
on eosinophilia with Colistin treatment in pediatric and 
neonatal patients. A prospective study is needed to evalu-
ate the clinical implications of such a side effect.
Our study provides physician taking care of neonatal 
patients with valuable information regarding the treat-
ment of multidrug resistant Acinetobacter species with 
Colistin. This is a retrospective study. No universal pro-
tocol was used for the patients. The factors that might 
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Fig. 1 Eosinophils count pre‑Colistin and Post Colistin treatment in 
14 patients
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